The Transcription Factor EB pipeline drugs market research report outlays comprehensive information on the Transcription Factor EB targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transcription Factor EB pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, and Gastrointestinal which include the indications Alzheimer’s Disease, Parkinson’s Disease, and Metabolic Dysfunction-Associated Steatohepatitis (MASH). It also reviews key players involved in Transcription Factor EB targeted therapeutics development with respective active and dormant or discontinued products.
The Transcription Factor EB pipeline targets constitutes close to five molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 2, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Transcription Factor EB overview
Transcription Factor EB (TFEB) is a master regulator of lysosomal and autophagy-related gene expression, playing a pivotal role in cellular homeostasis and the maintenance of cellular health. TFEB belongs to the microphthalmia/transcription factor E (MiT/TFE) family of basic helix-loop-helix leucine-zipper transcription factors. Its primary function is to orchestrate the transcriptional activation of genes involved in lysosomal biogenesis, autophagy, and the clearance of cellular waste. Under normal cellular conditions, TFEB is phosphorylated and resides in the cytoplasm. However, in response to various cellular stressors, such as nutrient deprivation or the accumulation of damaged organelles, TFEB undergoes dephosphorylation and translocate into the nucleus. In the nucleus, TFEB binds to the Coordinated Lysosomal Expression and Regulation (CLEAR) element in the promoter regions of target genes, thereby activating their transcription. The activation of TFEB-mediated gene expression promotes the synthesis of lysosomal enzymes, membrane proteins, and components of the autophagy machinery. TFEB’s role extends beyond cellular homeostasis; dysregulation of TFEB has been implicated in various diseases, including neurodegenerative disorders and metabolic conditions.
For a complete picture of Transcription Factor EB’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
